All In Biotech

Drug Trial Radar · NCT07021794

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

Effectiveness of Treating Post-COVID-19 Conditions (Long COVID) With the SARS-CoV-2 Specific Monoclonal Antibody, Sipavibart

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Nancy KlimasAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Florida Department of Health
First posted
Jun 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.

Conditions

  • Post-COVID / Long-COVID

Interventions

  • PlaceboDrug

    A single dose of placebo (saline) indistinguishable from the active drug in appearance

  • SipavibartBiological

    A single intramuscular dose of Sipavibart, 300 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient-Reported Outcomes Measurement Information System-29Time frame: 12 weeks
  2. Review of Treatment Related Adverse EventsTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nova Southeastern University

    Fort Lauderdale, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.